Ciprofloxacin, solution for infusion 2 mg / ml

Sector: Pharmaceuticals
Price: Contract Price
Packaging: 100 ml in glass bottles for blood
Terms of Delivery: FCA (Incoterms 2010)
Full Product Information:
Ciprofloxacin is active against most gram-negative microorganisms: Pseudomonas aeruginosa, hemophilic and intestinal rods, shigella, salmonella, meningococcus, gonococcus, some varieties of enterococci; many strains of staphylococci (producing and not producing penicillinillase), campylobacter, legionella, mycoplasmas, chlamydia, mycobacteria; as well as microorganisms producing beta-lactamases. Resistance to the drug: Ureaplasma urealyticum, Clostridium difficile, Nocardia asteroides. The action against Treponema pallidum has not been adequately studied. The rapid bactericidal action of ciprofloxacin is associated with its unique character of action. Ciprofloxacin, like other fluoroquinolones, blocks bacterial DNA-gyrase and disrupts the function of DNA, which causes the death of bacteria. Ciprofloxacin damages the membrane of the bacterial cell, which leads to the release of cellular contents. It is effective both in the bacterial growth phase and in the resting phase, it is also active against intracellular bacteria. The drug has a significant postantibiotic effect - up to six hours - and thus prevents the growth of bacteria. Indications for use. Adults. Uncomplicated and complicated infections caused by ciprofloxacin-susceptible pathogens: - respiratory tract infections. For out-patient treatment of pneumonia caused by pneumococci, ciprofloxacin should not be used as a first-choice drug. Ciprofloxacin is recommended for the treatment of pneumonias caused by Klebsiella spp., Enterobacter spp., Proteus spp., Escherichia coli, Pseudomonas aeruginosa, Haemophilus spp., Moraxella catarrhalis, Legionella and staphylococci; - infections of the middle ear and paranasal sinuses; - eye infections; - infections of the abdominal cavity, bacterial infections of the gastrointestinal tract, gallbladder and bile ducts, as well as peritonitis; - infections of the kidneys and urinary tract; - infections of the pelvic organs (gonorrhea, adnexitis, prostatitis); - skin and soft tissue infections; - infections of bones and joints; - sepsis; - prevention and treatment of infections in patients with weakened immunity (including - during treatment with immunosuppressants and neutropenia). Children. As a second or third line drug for the treatment of complicated infections of the urinary tract and pyelonephritis caused by E. coli in children aged 1 year and also for the treatment of pulmonary exacerbations caused by Pseudomonas aeruginosa in children with cystic fibrosis of the lungs aged 5 years. For adults and children. Reduction of the risk of contraction or progression of the disease by anthrax after aerogenic contact with Bacillus anthracis.

Another products from the category "Pharmaceuticals"

Hamoven is an original medicinal product, solution for infusions belonging to blood substitutes and protein fraction of blood plasma.
Reogemin is polyionic solution for infusion which belongs to a group of plasma substituting and perfusion solutions.
Plasma substituting and perfusion solutions. Electrolyte solution. 9 mg/ml isotonic infusion solution of sodium chloride is colourless transparent liquid. The solution is produced sterile and non-pyro...